Ono Shin, Ohuchi Hideo, Miyazaki Aya, Yamada Osamu
Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565, Japan.
Pediatr Cardiol. 2018 Oct;39(7):1290-1298. doi: 10.1007/s00246-018-1893-9. Epub 2018 May 22.
Protein-losing enteropathy (PLE) is a life-threatening complication in patients following the Fontan operation. However, PLE also develops in some patients with congenital heart disease (CHD) after biventricular repair (BVR). This study compared clinical profiles of PLE patients following the Fontan operation with those after BVR. We retrospectively reviewed clinical charts of postoperative CHD patients with PLE. The study population comprised 42 PLE patients (14BVR, 28Fontan). Postoperative follow-up period until onset was significantly shorter in the Fontan group than in the BVR group (14 ± 2 vs. 8 ± 1 years, p = 0.02), while there was no difference in PLE onset age between groups. Furthermore, there were no differences in prevalence of clinically relevant arrhythmias, cardiac output, or central venous pressure between the two groups at PLE onset. Percentage of structural lesions (valve regurgitation and/or stenotic lesions) responsible for development of PLE and ventricular end-diastolic pressure were higher in the BVR group than in the Fontan group (93 vs. 50%, p < 0.01), (13.4 ± 6.3 vs. 7.5 ± 4.1, p < 0.0001). Catheter intervention was applied in 2Fontan and 6BVR patients, while surgical intervention was required in 8BVR and 7Fontan patients. Of these, catheter intervention was effective in 2 (25%, 1Fontan, 1BVR) and surgical intervention was effective in 4 (26.7%, 1Fontan, 3BVR). Only one patient (5.3%) improved without intervention. Complete PLE remission rate was higher in the BVR group than in the Fontan group (38 vs. 7%, p = 0.02). During follow-up, death of 2 BVR and 8 Fontan patients occurred. There were no group differences in 5- to 10-year survival rates after PLE onset (81 vs. 81%, BVR, 81 vs. 66%, Fontan). Although BVR patients may have greater chance of PLE remission when compared with those exhibiting Fontan pathophysiology, mortality in PLE-CHD patients was significantly high regardless of postoperative hemodynamics.
蛋白丢失性肠病(PLE)是接受Fontan手术患者的一种危及生命的并发症。然而,一些双心室修复(BVR)后的先天性心脏病(CHD)患者也会发生PLE。本研究比较了Fontan手术后PLE患者与BVR后PLE患者的临床特征。我们回顾性分析了术后患有PLE的CHD患者的临床病历。研究人群包括42例PLE患者(14例BVR,28例Fontan)。Fontan组术后至发病的随访期明显短于BVR组(14±2年 vs. 8±1年,p = 0.02),而两组间PLE发病年龄无差异。此外,两组在PLE发病时临床相关心律失常的患病率、心输出量或中心静脉压方面无差异。BVR组中导致PLE发生的结构性病变(瓣膜反流和/或狭窄病变)的百分比和心室舒张末期压力高于Fontan组(93% vs. 50%,p < 0.01),(13.4±6.3 vs. 7.5±4.1,p < 0.0001)。2例Fontan患者和6例BVR患者接受了导管介入治疗,8例BVR患者和7例Fontan患者需要手术干预。其中,导管介入治疗有效的有2例(25%,1例Fontan,1例BVR),手术干预有效的有4例(26.7%,1例Fontan,3例BVR)。仅1例患者(5.3%)未经干预病情改善。BVR组的PLE完全缓解率高于Fontan组(38% vs. 7%,p = 0.02)。随访期间,2例BVR患者和8例Fontan患者死亡。PLE发病后5至10年生存率在两组间无差异(BVR组为81%,Fontan组为81%;BVR组为81%,Fontan组为66%)。尽管与表现为Fontan病理生理的患者相比,BVR患者PLE缓解的机会可能更大,但无论术后血流动力学如何,PLE-CHD患者的死亡率都显著较高。